Pfizer launches legal action to block Xeljanz copies in India

September 9, 2016
Medical Communications, Sales and Marketing Pfizer, Sun Pharma, Xeljanz, Zydus Cadila, rheumatoid arthritis

Pfizer has pre-emptively sued a number of India-based drug companies including Sun Pharma and Zydus Cadila to block any attempts …

FDA approves Dechra’s generic antibiotic

September 9, 2016
Medical Communications, Sales and Marketing Dechra, Putney, antiobiotic, generic

Dechra has announced that the US Food and Drug Administration (FDA) has approved its generic antibiotic. The product will be …

Apple introduce stricter entry requirements for health apps

September 8, 2016
Medical Communications, Research and Development Apple, Guidelines, apps, iphone, strict

Apple has toughened its stance on health and medical apps that can be bought and downloaded on the iOS App …

Retrophin announces positive Phase II results, Shkreli claims credit

September 8, 2016
Research and Development Phase II, Retrophin, Shkreli, rare kidney disease

Retrophin has announced positive top-line results for trial drug sparsentan in Phase II to treat a rare kidney disorder with …

Celgene and Agios to file FDA application for “first-in-class” cancer drug

September 8, 2016
Research and Development, Sales and Marketing Celgene, FDA, NDA, acute myeloid leukaemia, agios

According to an SEC 8-K filing by Agios, the company and its partner Celgene intend to file a new drug …

Takeda begins Phase III dengue vaccine trial

September 8, 2016
Research and Development Takeda, Vaccine, dengue, dengue vaccine, phase III, trial

Takeda Pharmaceuticals has announced the initiation of a global Phase III clinical trial to test its live-attenuated tetravalent dengue vaccine …

Clinical Trial Transparency

September 8, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trial, clinical trial transparency, transparency

Amid the global political and economic turmoil taking place, one small pharma story got much less attention than it should …

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

September 7, 2016
Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …

Pfizer appoints new chief scientific officer for neuroscience research

September 7, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Dr Ole Isacson has been named as the chief scientific officer at Pfizer’s neuroscience research unit. He will continue to …

Allergan CEO outlines ‘social contract with patients’

September 7, 2016
Research and Development, Sales and Marketing Allergan, Brent Saunders, CEO, blog

Highlighting a recent shift in the priorities of the pharmaceutical industry, Allergan CEO and president Brent Saunders has outlined a …

Tonix tanks after Phase III failure

September 7, 2016
Research and Development PTSD, fibromylagia, phase III failure, tonix, tonix pharmaceuticals

New York-based Tonix Pharmaceuticals has suffered an almost 60% fall in their share price, after the announcement that its fibromyalgia …

Allergan acquires biotech Retrosense for $60 million

September 7, 2016
Research and Development, Sales and Marketing Allergan, Retrosense, acquisition

Allergan has announced that it has acquired Retrosense, a biotech focused on novel gene therapy approaches to restore vision in …

Antitrust investigation launched into Mylan and the EpiPen scandal

September 7, 2016
Research and Development, Sales and Marketing Mylan, US, antitrust, epipen, investigation, lawmakers, scandal

The New York attorney general has commenced an investigation into Mylan Pharmaceuticals, after an initial review indicated that the company …

European Commission approves new RA treatment from BMS

September 6, 2016
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis

Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …

Bayer takes another shot at Monsanto acquisition

September 6, 2016
Manufacturing and Production, Sales and Marketing Bayer, acqusition, monsanto

Bayer has made another move to acquire US-based Monsanto, raising the price it is prepared to pay in an effort …

Eisai “cannot understand” German agency’s recommendation to reject Halaven

September 6, 2016
Manufacturing and Production, Research and Development Eisai, Germany, Halaven, IQWIG, german

Eisai has issued a statement to declare their “bewilderment” following a decision from the German Institute for Quality and Efficiency …

Taiho invests in Arcus Biosciences as part of $70 million deal

September 6, 2016
Manufacturing and Production, Sales and Marketing Arcus, investment, taiho

Taiho Ventures has invested in California-based Arcus Biosciences alongside GV, Invus, DROIA Oncology Ventures and Stanford University as part of …

Horizon and Fulcrum Therapeutics form CRISPR collaboration

September 6, 2016
Manufacturing and Production, Research and Development Horizon Discovery, crispr, fulcrum, fulcrum therapeutics, gene editing, horizon, rare diseases

Horizon Discovery has announced that it has entered into a partnership with Fulcrum Therapeutics to utilise Horizon’s CRISPR-based screening platform …

Non-invasive ventilation touted for COPD treatment at respiratory meeting

September 6, 2016
Manufacturing and Production, Research and Development COPD, resmed

ResMed has presented results at the European Respiratory Society international congress, touting home non-invasive ventilation (NIV) as part of a …

The Gateway to Local Adoption Series

Latest content